BTYNB
BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA (IC50=5 μM) . BTYNB exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB can be used for cancer research[1].
Product Specifications
CAS Number
[304456-62-0]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
C-Myc
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/btynb.html
Concentration
10mM
Purity
98.0
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=CC=C1/N=C/C2=CC=C(S2)Br)N
Molecular Formula
C12H9BrN2OS
Molecular Weight
309.18
Precautions
H302, H315, H319, H335
References & Citations
[1]Lily Mahapatra, et al. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation. Transl Oncol
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
SARS-CoV-2 (2019-nCoV) Spike RBD(A352S)-His Recombinant HEK293 Cell Lysate (WB positive control)
SARS-CoV-2 (2019-nCoV) Spike RBD(A352S)-His Recombinant HEK293 Cell Lysate (WB positive control)
